@article{2110,
  keywords = {Adjuvants, Immunologic, Cancer Vaccines, GTP Phosphohydrolases, Humans, leprosy, Malaria Vaccines, Merozoite Surface Protein 1, Mycobacterium bovis, Recombinant Proteins, Tuberculosis, Urinary Bladder Neoplasms},
  author = {Yamada T},
  title = {[Study on recombinant BCG].},
  abstract = {<p>The progress of study on recombinant BCG was stated briefly. And then our studies on recombinant BCG were mentioned. Recombinant BCG secreting alpha antigen-fused merozoite surface protein 1 (MSP 1) was prepared and tested for its ability to control infections of Plasmodium yoelii. Result turned out it controlled the infection better than recombinant MSP 1 mixed with Freund incomplete adjuvant did. Recombinant BCG secreting excess amounts of antigen 85 complex A controlled infection of Mycobacterium leprae. Addition of recombinant BCG secreting alpha antigen-fused IL-2 to peritoneal exudate cells induced IFN-gamma resulting in killing bladder cancer cells more efficiently than parental BCG did.</p>},
  year = {2000},
  journal = {Kekkaku : [Tuberculosis]},
  volume = {75},
  pages = {517-20},
  month = {2000 Aug},
  issn = {0022-9776},
  language = {jpn},
}